Larry Robbins
SKIPGlenview Capital Management
Skilled healthcare hedge fund manager whose event-driven, long/short, policy-trading approach diverges significantly from our patient value philosophy.
Healthcare & Biotech Specialists
Score Breakdown
Investment Philosophy & Portfolio Style
Philosophy
Robbins employs a fundamental, research-intensive long/short equity approach with a heavy concentration in healthcare services. His philosophy is rooted in deep industry analysis rather than pure value investing. He looks for companies where regulatory or policy changes create mispriced opportunities — his famous ACA (Obamacare) trade in 2013-2014 was based on the thesis that hospital stocks were massively underpriced relative to the benefit they would receive from healthcare reform. He is willing to take large, concentrated positions and has activist tendencies, pushing for operational improvements and strategic changes. His approach is more event-driven and thesis-driven than traditional buy-and-hold value investing.
Portfolio Style
Moderately concentrated long/short equity fund, typically 20-40 positions. Heavy healthcare services weighting (hospitals, managed care, pharma services) — often 50-70% of the portfolio in healthcare. Uses leverage and short positions. Willing to take 5-10% positions in high-conviction ideas. Portfolio turnover is moderate — holds positions for 1-3 years typically, not decades. Has made sector-specific macro bets (e.g., betting on ACA beneficiaries as a group). Also holds positions in technology and industrials but healthcare is the core competency.
Background
Larry Robbins founded Glenview Capital Management in 2000 after working at Omega Advisors under Leon Cooperman. He graduated from the University of Pennsylvania and holds an MBA from Columbia Business School. Glenview grew into a major hedge fund with AUM peaking around $10-13 billion. Robbins is known as one of the premier healthcare-focused hedge fund managers on Wall Street, with deep expertise in managed care, hospital systems, and healthcare services. He has been a prominent speaker at investment conferences including Ira Sohn and SALT. He returned outside capital in 2020 to run Glenview as more of a family office/smaller fund structure.
Track Record
Glenview delivered strong returns in its first 15 years, compounding at roughly 15-20% annualized from 2000-2015. The ACA trade in 2013 was legendary — the fund returned approximately 40-50% that year by loading up on hospital stocks like HCA and Tenet Healthcare before the ACA rollout. However, performance became more volatile after 2015. The fund suffered significant losses in 2016 and had mixed results in 2017-2019. Robbins returned outside capital around 2020, effectively downsizing the operation. The transition to a smaller structure suggests the large-fund model became challenging. Overall track record is strong but with notable drawdowns, and the fund's best years were concentrated in specific policy-driven trades.
Notable Holdings
Historical major positions include HCA Healthcare, Tenet Healthcare, Cerner (before acquisition), McKesson, Cigna, Humana, Change Healthcare, and various managed care and hospital names. In recent years, the portfolio has included technology positions alongside healthcare. His most famous trade was the concentrated bet on hospital stocks ahead of ACA implementation in 2013-2014.
Transparency & Integrity
Transparency(Score: 5/10)
Moderate transparency. Files 13F reports quarterly. Robbins has been a frequent speaker at hedge fund conferences and has shared investment theses publicly at events like the Ira Sohn Conference. However, as a hedge fund, detailed performance data and position-level P&L are not publicly available. The decision to return outside capital reduced public disclosure requirements. He has been relatively open about his macro healthcare views and policy analysis.
Integrity(Score: 7/10)
Generally good reputation on Wall Street. No major SEC enforcement actions or fraud allegations. His decision to return outside capital rather than continue extracting fees when performance deteriorated shows a degree of integrity. He has been a significant philanthropist, particularly in education. Some criticism of his aggressive activism and short-term policy trading, but no ethical red flags. His close ties to industry and policy circles raise some questions about information advantages but nothing improper has been alleged.
Relevance to Us
Limited alignment. Robbins is a skilled healthcare analyst but his approach is fundamentally different from ours: he uses leverage, shorts, has moderate turnover, and makes policy-driven event bets rather than long-term buy-and-hold investments. His healthcare expertise is valuable for understanding the sector, but his trading style — event-driven, policy-dependent, activist — does not match our patient, long-only, concentrated value approach. His best returns came from correctly predicting ACA policy outcomes, which is not the type of thesis we pursue. The fact that he returned outside capital suggests the strategy's scalability limits. His healthcare industry knowledge could be useful as sector context, but his positions should not be copied as long-term holdings.